-
20 pharmacies were investigated and these problems frequently occurred
Time of Update: 2022-03-06
In January this year, a total of 6 pharmacies in Bozhou failed to pass the inspection due to the problem of "(licensed) pharmacists not on duty".
-
Shanghai announces the list of the first batch of restricted pharmacy drugs to be purchased online in 2022
Time of Update: 2022-03-06
Drug Information Announcement On February 15, 2022, the drug information will be pushed to designated pharmacies through the "Shanghai Pharmaceutical Procurement Service and Supervision Information System" (hereinafter referred to as the Sunshine Platform), which will take effect on February 17, 2022 .
-
Huang Xiaodong, Deputy General Manager and Secretary of the Board of Directors of Fuxiang Pharmaceutical, resigned
Time of Update: 2022-03-06
On the evening of February 14, Fuxiang Pharmaceutical announced that Huang Xiaodong resigned from the company's deputy general manager and board secretary due to personal reasons, and would no longer hold any positions in the company after his resignation .
-
Since 2022, 28 pharmaceutical companies have launched buybacks
Time of Update: 2022-03-06
, and repurchase shares in a centralized bidding transaction, and the shares to be repurchased will be used to implement employee stock ownership plans or equity incentives .
-
Novel drug development for endometriosis: GnRH antagonist competition and nonhormonal target exploration
Time of Update: 2022-03-06
By April ChenAt present, the main development direction of new EMs drugs is focused on GnRH antagonists that inhibit estrogen levels, such as AbbVie Elagolix, Pfizer Relugolix, etc.
-
In 2022, localities will continue to vigorously promote the inheritance, innovation and development of traditional Chinese medicine
Time of Update: 2022-03-06
For example, since December 2021, four national-level policies have been issued, including the "Guiding Opinions on Medical Insurance Supporting the Inheritance and Innovation of Traditional Chinese Medicine" .
-
The first subject enrolled in the Phase III clinical trial of Yuandong Bio-Udagliptin in the treatment of type 2 diabetes mellitus
Time of Update: 2022-03-06
Eudagliptin Tablets is a new class 1 chemical drug independently developed by the company and is the first oral DPP-4-week preparation for the treatment of type 2 diabetes in China .
-
The financial reports of multinational pharmaceutical companies have been released one after another, and the revenue of many companies in China has exceeded 16 billion yuan
Time of Update: 2022-03-06
According to the 2021 annual report released by Merck, the company's revenue in 2021 will increase by 17% year-on-year to $48.
Roche According to Roche's recently released 2021 financial report, the company's sales in 2021 will increase by 8% year-on-year to 62.
-
The Offensive and Defensive Way of Pharmaceutical Licensing Transactions
Time of Update: 2022-03-06
This requires the licensor and the licensee to clearly agree on their respective rights and obligations at all stages of research and development, production and commercialization in the pharmaceutical licensing agreement .
-
Domestic pharmaceutical companies are attacking innovative drugs, but these problems remain to be solved
Time of Update: 2022-03-06
In addition to Pien Tze Huang, many pharmaceutical companies have been increasing investment in the research and development of innovative drugs in recent years.
-
Haisco's innovative drug HSK36212 capsule received the "Notice of Acceptance" for clinical trial application
Time of Update: 2022-03-06
Preclinical studies have shown that HSK36212 capsules can inhibit the expression of genes related to renal injury and fibrosis at the molecular level in animal models of acute kidney injury and chronic kidney disease; Reducing the inflammatory response, in the detection of renal biochemical function, can increase the UPCR ratio and improve blood biochemical indicators, showing a huge potential for the treatment of renal disease .
-
In 2022, the field of medicine and biology will still be favored by research institutions
Time of Update: 2022-03-06
Specifically, according to the investor relations activity record sheet released by Mindray Medical on January 17, 2022, from January 4 to January 7, January 10 to January 14, and January 17, the company received a total of 742 participants from 430 institutions .
-
A new batch of generic drug reference preparation catalogues are announced!
Time of Update: 2022-03-06
On January 7, 2022, the catalogue of generic drug reference preparations (the 50th batch) was released, and a total of 70 varieties were included.
It is understood that since 2016, China has released a total of 51 batches of chemical generic drug reference preparation catalogues.
-
In 2022, mergers and acquisitions of biopharmaceutical companies may be more active
Time of Update: 2022-03-06
Among them, in terms of merger and acquisition value, there are at least 4 transactions with a value of more than 10 billion US dollars, including Australian biotechnology companies CSL, Thermo Fisher, Merck and Siemens .
-
Under favorable policies, the growth of innovative traditional Chinese medicine drugs can be expected
Time of Update: 2022-03-06
In order to encourage the innovation of traditional Chinese medicine, in recent years, policies on promoting the innovation of traditional Chinese medicine, examination and approval, development of formula granules, medical insurance and payment, and personnel training have been issued frequently .
-
ASCO GU: PARP inhibitor PK game Lynparza may be better than Zejula in prostate cancer
Time of Update: 2022-03-06
PROpel in newly diagnosed metastatic castration resistance with or without homologous recombination repair (HRR) mutations In men with prostate cancer (mCRPC), Lynparza + Zytiga + steroids reduced the risk of disease progression or death by 34% compared to standard-of-care therapy Zytiga (abiraterone acetate) + steroids (HR=0.
-
The national procurement of proprietary Chinese medicines is approaching, and pharmaceutical machine companies usher in new opportunities
Time of Update: 2022-03-06
In recent years, the local government has also carried out a centralized procurement pilot for some varieties of Chinese patent medicines with large demand and high amount, and achieved certain results .
-
Breakthrough Research Progress of Small Molecule Anti-COVID-19 Drugs
Time of Update: 2022-03-05
Currently, drug development for SARS-CoV-2 mainly targets one or more events in the viral life cycle to prevent viral replication, such as blocking the binding of the spike protein to angiotensin-converting enzyme 2 (ACE2) and inhibiting the virus Membrane fusion with host cells or inhibition of 3CL protease (3C-likeprotease, 3CLpro) and papain (PLpro) or inhibition of RNA-dependent RNA polymerase (RdRp) and so on .
-
Junshi Biosciences Announces Latest Data on Urothelial Carcinoma of PD-1 Inhibitor
Time of Update: 2022-03-05
At this ASCO-GU conference, the POLARIS-03 study once again updated the 2-year survival data and biomarker analysis results of toripalimab in patients with advanced urothelial carcinoma who had failed previous systemic therapy.
-
A large number of pharmacies have been rectified, and these problems should be paid attention to
Time of Update: 2022-03-05
Among them, it is worth noting that in January, a total of 6 pharmacies in Bozhou failed to pass the inspection due to the problem of "(licensed) pharmacists not on duty", and 1 pharmacy was even put on file for investigation, and the remaining 5 were investigated according to the severity of the circumstances.
